创新药近期利好催化不断，科创医药ETF嘉实(588700)交投活跃，近一周日均成交同类第一！

Group 1: ETF Performance - The liquidity of the Science and Technology Innovation Pharmaceutical ETF (嘉实) showed an intra-day turnover of 14.75%, with a transaction volume of 29.7999 million yuan, indicating active market trading [2] - Over the past year, the ETF's scale increased by 125 million yuan, ranking first among comparable funds [2] - The ETF's net asset value rose by 20.29% over the past year, with the highest monthly return since inception being 23.29% and an average monthly return of 8.18% [2] Group 2: Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index accounted for 51.6% of the index, with leading companies including 联影医疗 (8.97%), 百济神州 (7.05%), and 惠泰医疗 (5.85%) [2][4] Group 3: Regulatory Updates - The National Medical Products Administration released a draft announcement to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [4] Group 4: Industry Events - The American Diabetes Association Annual Meeting (ADA) will take place from June 20 to 23, showcasing key clinical advancements in GLP-1RA research and related medications [5]